Intersect ENT, Inc. (XENT) Subject Of A Class Action Lawsuit

Intersect ENT, Inc. (XENT), a publicly-traded company that makes medical implants, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company.

Intersect Class Period And Lead Plaintiff Deadline

Investors who purchased shares of Intersect between August 1, 2018 and May 6, 2019 (the class period) may be eligible to participate in the lawsuit, which concerns violations of federal securities laws.

The deadline to apply to the court to be appointed as lead plaintiff, also called class representative, is July 15, 2019.

The lawsuit alleges that Intersect made false and misleading statements related to its SINUVA sinus implant. The company didn’t have enough “reimbursement representatives to ensure physicians’ access to SINUVA,” which led to the company’s sales force concentrating on reimbursement rather than sales growth. Due to the issues with reimbursement, doctors were less likely to use Intersects products.

When the market learned of these issues, investors suffered damages

Recovering Money Lost With Intersect ENT, Inc. (XENT) Stock

If you suffered losses with Intersect ENT, Inc., you may be able to recover some of your losses by participating in the lawsuit.

Silver Law Group represents the interests of investors who have been the victims of investment fraud. Our attorneys represent investors in class actions against issuers in state or federal court and investors in securities arbitration claims against Wall Street firms for stockbroker misconduct. Scott Silver is the chairman of the Securities and Financial Fraud Group of the American Association of Justice and represents investors nationwide in securities investment fraud cases. Please contact Scott Silver of the Silver Law Group for a free consultation at ssilver@silverlaw.com or toll free at (800) 975-4345.